M.D. Anderson to Hold Conference in Spanish

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

HOUSTON--The University of Texas M.D. Anderson Cancer Center will hold its second medical oncology conference in Spanish on May 22-24, 1996. The educational conference will bring together physicians from Spain and Latin American with the M.D. Anderson faculty, said Richard Pazdur, MD, associate professor of medicine and co-director of the conference along with Alejandro Preti, MD, assistant professor of medicine.

HOUSTON--The University of Texas M.D. Anderson Cancer Center willhold its second medical oncology conference in Spanish on May22-24, 1996. The educational conference will bring together physiciansfrom Spain and Latin American with the M.D. Anderson faculty,said Richard Pazdur, MD, associate professor of medicine and co-directorof the conference along with Alejandro Preti, MD, assistant professorof medicine.

"I think M.D. Anderson is unique in that it has such a diversegroup of Spanish-speaking faculty, both native speakers and thosewho learned the language along the way," Dr. Pazdur saidin an interview. Most of the speakers are M.D. Anderson faculty.In addition, physicians from Spain have been invited to discusstheir research work at a symposium to be held in conjunction withthe conference.

ASCO Findings Will Be Reviewed

The meeting will also provide an opportunity for a discussionof studies presented at the 1996 American Society of ClinicalOncology (ASCO) meeting, to put new findings into the contextof existing therapies, Dr. Pazdur said. He expects between 50and 100 physicians to attend the conference.

Related Videos
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.